Plain-language check: Category 2 removal ≠ Bulks List ≠ FDA approval

The Regulatory page walks April 2026 (nominations withdrawn → off interim Category 2) versus July 2026 PCAC recommendation to list Semax free base/acetate on the 503A Bulks List—and stresses FDA still must decide and typically complete notice-and-comment rulemaking. What’s still confusing in that sequence for you? Prefer primary FDA/meeting materials over Telegram summaries. Not legal advice.